| 发明名称 |
ORAL PHARMACEUTICAL FORMULATION OF OMARIGLIPTIN |
| 摘要 |
The present invention is directed to stable, oral pharmaceutical formulations of dipeptidyl peptidase-4 inhibitors, such as omarigliptin. Such pharmaceutical formulations comprise omarigliptin; and neutral excipients, wherein the neutral excipient is present in the amount of at least 75% by weight of the pharmaceutical formulation and comprises at least one non-reducible sugar diluent or a mixture of non-reducible sugar diluents. |
| 申请公布号 |
US2016166544(A1) |
申请公布日期 |
2016.06.16 |
| 申请号 |
US201414906085 |
申请日期 |
2014.08.25 |
| 申请人 |
Cooper Vincent Brett;Bradley Kathryn Alanna;PYGALL Samuel Robert;GUPTA Rajan;Stanford Madison Paige;XIE Lin;Merck Sharp & Dohme Corp. ;Merck Sharp & Dohme Limited |
发明人 |
Cooper Vincent Brett;Bradley Kathryn Alanna;Pygall Samuel Robert;Gupta Rajan;Stanford Madison Paige;Xie Lin |
| 分类号 |
A61K31/4162;A61K9/20;A61K47/12;A61K9/00;A61K47/26;A61K47/38 |
主分类号 |
A61K31/4162 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A stable oral pharmaceutical formulation comprising:
omarigliptin; and at least 75% by weight of the pharmaceutical formulation comprise neutral excipients, wherein the neutral excipients comprise at least one non-reducible sugar diluent. |
| 地址 |
Cheshunt GB |
